Perspective Therapeutics, Inc. 8-K

What Happened
Perspective Therapeutics, Inc. (CATX) announced it entered into an underwriting agreement on February 2, 2026 and closed an underwritten offering on February 3, 2026. The Offering consisted of 39,576,088 shares of common stock and, in lieu of some shares, pre‑funded warrants to purchase 6,598,046 shares. The public price was $3.79 per share and $3.789 per pre‑funded warrant, and the gross proceeds to the company were approximately $175 million before underwriting discounts, commissions and expenses.

Key Details

• Offering size and price: 39,576,088 common shares at $3.79 each; 6,598,046 pre‑funded warrants at $3.789 each; gross proceeds ≈ $175 million.
• Use of proceeds: to advance clinical development, invest in manufacturing facilities, and for working capital and general corporate purposes; may also be used for acquisitions or investments though none are committed.
• Warrant terms: Pre‑funded warrants do not expire, are exercisable for cash or via cashless exercise, and include ownership caps (holders cannot exercise to exceed 4.99% or 9.99% ownership unless elected; this cap can be adjusted up to 19.99% with 61 days’ notice).
• Underwriters and legal: Piper Sandler & Co. and UBS Securities LLC acted as representatives; offering was made under the company’s S-3 shelf (File No. 333-279692, effective April 8, 2025); Hogan Lovells US LLP provided a legal opinion.

Why It Matters
The transaction meaningfully increases Perspective Therapeutics’ cash resources, supporting its stated near‑term priorities—clinical programs and manufacturing—which can reduce near‑term financing risk. However, the issuance dilutes existing shareholders and introduces outstanding pre‑funded warrants that may convert into additional shares. The company disclosed no current acquisition commitments despite stating proceeds could be used for such purposes. Copies of the pricing press release and updated corporate presentation were filed as exhibits.